標的肺がん治療に役立つ新技術を開発(Novel tech could aid targeted lung cancer treatment)

ad

2026-07-13 エディンバラ大学

英国エディンバラ大学とNHSロージアンの研究チームは、蛍光寿命イメージング顕微鏡(FLIM)と人工知能(AI)を組み合わせ、肺がんの原因となるEGFR遺伝子変異を迅速かつ高精度に予測する新技術を開発した。従来は遺伝子シーケンスなど時間と費用を要する検査が必要であったが、本手法は未染色・未処理の生検組織が発する自然蛍光を解析し、AIがEGFR変異の有無や治療方針に重要な2種類の主要変異を高精度で識別する。組織を消費しないため、限られた生検試料を追加検査に利用できる利点もある。近年の肺がん検診拡大に伴い診断件数が増加する中、本技術は診断時間を数週間から数分へ短縮し、検査コストも大幅に削減できる可能性がある。研究チームは今後、臨床での有効性を検証するとともに、他のがん種や標的遺伝子への適用、診療ワークフローへの導入を進め、個別化医療の実現を目指している。

<関連情報>

肺腺癌における蛍光寿命イメージングと深層学習を用いたEGFR変異状態のラベルフリー予測 Label-Free Prediction of EGFR Mutation Status Using Fluorescence Lifetime Imaging and Deep Learning in Lung Adenocarcinoma

Zhenya Zang;David A. Dorward;Sophie Ihuoma;Ahsan R. Akram;Qiang Wang
Cancer Research  Published:July 13 2026
DOI:https://doi.org/10.1158/0008-5472.CAN-25-5589

標的肺がん治療に役立つ新技術を開発(Novel tech could aid targeted lung cancer treatment)

Abstract

Accurate prediction of epidermal growth factor receptor (EGFR) mutations is essential for guiding targeted therapy in non–small cell lung cancer (NSCLC) and is routinely performed in clinical pathology samples. Current diagnostic practices rely on molecular techniques such as PCR-based assays and next-generation sequencing, which are often costly, time-consuming, and destructive to tissue samples. Furthermore, in NSCLC diagnostics, a common limitation is the availability of sufficient tissue to support comprehensive pathologic and molecular characterization, highlighting the need for noninvasive, predictive approaches to identify EGFR mutations. Recent advances in computational pathology have enabled the rapid prediction of EGFR mutations from histopathologic images using deep learning (DL), demonstrating promising performance. However, these methods still depend on conventional tissue staining. In this study, we developed a DL-based nondestructive, label-free approach for rapid and accurate EGFR mutation prediction using fluorescence lifetime imaging (FLIM). Unlike existing methods, this approach eliminated the need for histologic staining and molecular testing, and it achieved state-of-the-art area under the receiver operating characteristic curve scores of 0.966 on label-free FLIM images. This strategy also provided accurate classification of the two most common NSCLC EGFR mutations of exon 19 deletion and exon 21 point mutation across the dataset. Together, this work demonstrates the strength of label-free FLIM images for mutation prediction, which could significantly reduce clinical overhead associated with lengthy gene sequencing and staining procedures to accelerate practical, nondestructive mutation prediction.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました